| Description | Cp-690550a is a novel JAK3 inhibitor, which is used to treat rheumatoid arthritis, graft rejection, psoriasis, and other immune-mediated diseases. |
| Synonyms | Tofacitinib metabolite M2, CP-690,550A, UNII-Q7ZOK859UK |
| molecular weight | 303.36 |
| Molecular formula | C15H21N5O2 |
| CAS | 1243290-37-0 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Yamaoka K. Relation between disease modifying anti-rheumatic drugs and herpes zoster in rheumatoid arthritis. Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(3):181-9. doi: 10.2177/jsci.39.181. PubMed PMID: 27320933. 2. Radominski SC, Cardiel MH, Citera G, Goecke A, Jaller JJ, Lomonte AB, Miranda P, Velez P, Xibillé D, Kwok K, Rojo R, García EG. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies. Reumatol Clin. 2016 Jun 14. pii: S1699-258X(16)30040-7. doi: 10.1016/j.reuma.2016.04.010. [Epub ahead of print] English, Spanish. PubMed PMID: 27317492. 3. Tanaka Y. [Tofacitinib for the treatment of rheumatoid arthritis]. Nihon Rinsho. 2016 Jun;74(6):974-80. Japanese. PubMed PMID: 27311188. 4. Sterba Y, Ilowite N. Biologics in Pediatric Rheumatology: Quo Vadis? Curr Rheumatol Rep. 2016 Jul;18(7):45. doi: 10.1007/s11926-016-0593-9. Review. PubMed PMID: 27306623. |